No price history available.
Key financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | INRm | 10,671 | 8,615 | 2,373 | 1,871 | 1,491 | 1,163 | 700 | N/A | N/A |
| Operating profit | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | INRm | -1,091 | -778 | -677 | -3,285 | -454 | -320 | -1,765 | N/A | N/A |
| EPS reported | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Value | ||||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | ||||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | ||||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | ||||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Established in 1988 and headquartered in Hyderabad, India, Vivimed Labs Limited, along with its associated entities, is an international manufacturer and supplier of diverse products, including active pharmaceutical ingredients (APIs), finished drug formulations, specialized chemicals, and consumer-branded remedies. Its global presence extends across markets such as India, Mexico, Spain, and Hungary, among others. The company's operations are divided into two core segments: the Pharmaceutical Business and the Specialty Chemicals Business. Within its Pharmaceutical division, Vivimed Labs supplies APIs and crucial intermediates to both generic and ethical pharmaceutical companies. It also develops and markets proprietary branded formulations catering to therapeutic areas like ophthalmology, nutraceuticals, dermatology, and pain relief. Additionally, it provides contract manufacturing services for a variety of dosage forms, including capsules, tablets, syrups, liquids, nasal sprays, and ointments. A notable product is Favulous, manufactured for the treatment of mild to moderate COVID-19 cases. The Specialty Chemicals segment boasts a broad portfolio. This includes Jarocol-branded hair dye intermediates essential for permanent, semi-permanent, and temporary hair coloring systems, alongside oxidation dye couplers, bases, and direct and basic dyes. It also produces Reversacol-branded photochromic dyes and antimicrobial agents utilized in applications ranging from plastic additives to antibacterial handwashes. Furthermore, the company manufactures photographic chemicals, such as black and white developers and antifog additives, for medical and industrial X-ray imaging, consumer photography, and graphic arts litho-plate production. Collectively, Vivimed Labs' offerings find extensive application in the home, personal, and industrial care sectors.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Vivimed Labs Ltd. (VIVIMEDLAB.NS)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Established in 1988 and headquartered in Hyderabad, India, Vivimed Labs Limited, along with its associated entities, is an international manufacturer and supplier of diverse products, including active pharmaceutical ingredients (APIs), finished drug formulations, specialized chemicals, and consumer-branded remedies. Its global presence extends across markets such as India, Mexico, Spain, and Hungary, among others. The company's operations are divided into two core segments: the Pharmaceutical Business and the Specialty Chemicals Business. Within its Pharmaceutical division, Vivimed Labs supplies APIs and crucial intermediates to both generic and ethical pharmaceutical companies. It also develops and markets proprietary branded formulations catering to therapeutic areas like ophthalmology, nutraceuticals, dermatology, and pain relief. Additionally, it provides contract manufacturing services for a variety of dosage forms, including capsules, tablets, syrups, liquids, nasal sprays, and ointments. A notable product is Favulous, manufactured for the treatment of mild to moderate COVID-19 cases. The Specialty Chemicals segment boasts a broad portfolio. This includes Jarocol-branded hair dye intermediates essential for permanent, semi-permanent, and temporary hair coloring systems, alongside oxidation dye couplers, bases, and direct and basic dyes. It also produces Reversacol-branded photochromic dyes and antimicrobial agents utilized in applications ranging from plastic additives to antibacterial handwashes. Furthermore, the company manufactures photographic chemicals, such as black and white developers and antifog additives, for medical and industrial X-ray imaging, consumer photography, and graphic arts litho-plate production. Collectively, Vivimed Labs' offerings find extensive application in the home, personal, and industrial care sectors.
